TABLE 3.
Influenza vaccination strategy and anti-HLA class II antibody production.
|
% HLA Class II |
||||||
| N* | Baseline | 5 weeks after vaccination | N** | 10 weeks after vaccination | 1 year after vaccination | |
| Total cohort n-(%) | 490 | 78 (15.9) | 63 (14.0) | 260 | 28 (10.8) | 19 (7.1) |
| Vaccine composition n-(%) | ||||||
| Adjuvanted | 110 | 16 (14.5) | 19 (17.3) | |||
| Non-adjuvanted | 380 | 62 (16.3) | 51 (13.4) | |||
| Time from Transplant to vaccination n-(%) | ||||||
| ≤6 months | 59 | 9 (15.3) | 7 (11.8) | |||
| >6 months | 431 | 69 (16.0) | 62 (14.6) | |||
| Number of vaccine doses n-(%) | ||||||
| One dose | 130 | 9 (6.6) | 13 (9.5) | 130 | 11 (8.0) | 10 (7.3) |
| Two doses | 136 | 13 (10.0) | 9 (6.9) | 136 | 17 (13.0) | 9 (6.9) |
| Type of transplant n-(%) | ||||||
| Kidney | 153 | 31 (21.7) | 23 (18.1) | 64 | 9 (14.0) | 9 (14.0) |
| Liver | 155 | 29 (18.7) | 23 (15.9) | 70 | 6 (8.6) | 3 (4.3) |
| Heart | 95 | 12 (12.6) | 10 (11.7) | 55 | 6 (10.9) | 3 (5.4) |
| Lung | 92 | 4 (4.3) | 5 (5.9) | 75 | 6 (8.0) | 3 (4.0) |
| Combined (liver-kidney) | 5 | 2 (40.0) | 2 (40.0) | 3 | 1 (33.3) | 1 (33.3) |
Parameters were compared using the McNemar test or Chi-square test when appropriate. No differences were observed in all the analyses made. N*, number of individuals analyzed at baseline and at 5 weeks post-vaccination; N**, number of individuals analyzed at 10 weeks and at 1 year post-vaccination.